09/17/2019 Objective of session The objectives of the session were to discuss with the U.S. Food and Drug Administration (FDA)
Brendan Lee
As the lead patient advocacy organization of the Brittle Bone Disorders Consortium (BBDC), part of the NIH’s Rare Diseases Clinical